Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Bortezomib
Brand Name Velcade®
Payment Category Medicare Part B
Year Introduced 2003
Type of Drug Proteasome inhibitor
Manufacturer Millennium
Medical Affairs Questions (date verified) 866.835.2233
Coverage & Reimbursement Questions 866.835.2233
HCPCS J9041
Billing Unit 0.1 mg
Medicare Payment Limit (Effective January 1, 2021) $44.67

FDA-Approved Indication(s)

  • Indicated for the treatment of patients with 1) multiple myeloma or 2) mantle cell lymphoma. (6/9/17)

Approved Indication(s) with Orphan Drug Status 1) Treatment of multiple myeloma. 2) Treatment of mantle cell lymphoma.
ICD-10 Code(s) for Labeled Indication(s) Multiple myeloma [C90.0x]; Mantle cell lymphoma [C83.1x]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US